Posted by Michael Wonder on 07 Feb 2018
AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Maviret – an oral therapy for the treatment of patients with hepatitis C
6 February 2018 - Maviret previously received a Notice of Compliance from Health Canada on 16 August 2017.
AbbVie announced that the CADTH Canadian Drug Expert Committee (CDEC) issued a positive recommendation for Maviret (glecaprevir/pibrentasvir tablets), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6).
Maviret is the only 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment,* who make up a large portion of HCV patients in Canada.
